In respect of the alleged patent infringement action brought by Fertin Pharma A/S and Gumlink A/S against the Company relating to the sale of its nicotine gum products in Canada (the “Action”), Revolymer is pleased to announce that the Action, and the counterclaim forming part of Revolymer’s defence, has been settled and discontinued.